KRYS

Krystal Biotech, Inc.

NasdaqHealthcareBiological Products, (No Diagnostic Substances)

Insider activity for last month from 08/05 to 09/05. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.

Latest filingSep 04, 2026Most recent Form 4
Total buying$00 buys
Total selling$1.79B26 sells
Net open-market-$1.79B2 insiders
Open-market mix
Buy vs sell distribution by transaction count
26 transactions
0 buys0%·100%26 sells

Insider activity report

Monthly open-market purchase and sale counts
Buys Sells
30150-15-30transactionsAugSep 2026 sells: 26 transactions · $1.79B26Sep

Transaction codes

By Form 4 transaction code in selected period
26transactions
  • S · Open-market sells · dominant26 · 100%

Activity by reported role

A joint filing can contribute to multiple roles
52transactions
  • PRES · dominant26 · 50%
  • D13 · 25%
  • R13 · 25%

Distinct insiders active

Reporting-owner CIKs by month · peak Sep 2026 (2)
Aug 2026Sep 2026
2distinct insiders in 2 months

Reported Holdings After

Separated by insider, security, and ownership type
Krishnan Krish SCommon Stock · Direct
1.4M1.3MSep 04, 2026 · 1,372,023 shares owned afterSep 04, 2026 · 1,347,543 shares owned afterSep 04, 2026 · 1,347,948 shares owned afterSep 04, 2026 · 1,348,795 shares owned afterSep 04, 2026 · 1,350,153 shares owned afterSep 04, 2026 · 1,350,726 shares owned afterSep 04, 2026 · 1,352,736 shares owned afterSep 04, 2026 · 1,353,950 shares owned afterSep 04, 2026 · 1,356,216 shares owned afterSep 04, 2026 · 1,359,573 shares owned afterSep 04, 2026 · 1,362,716 shares owned afterSep 04, 2026 · 1,366,697 shares owned afterSep 04, 2026 · 1,369,994 shares owned afterSep 04, 2026Sep 04, 2026
1,369,994Sep 04, 2026
Krishnan SumaCommon Stock · Direct
1.3M1.3MSep 04, 2026 · 1,326,625 shares owned afterSep 04, 2026 · 1,302,145 shares owned afterSep 04, 2026 · 1,302,544 shares owned afterSep 04, 2026 · 1,303,370 shares owned afterSep 04, 2026 · 1,304,699 shares owned afterSep 04, 2026 · 1,305,264 shares owned afterSep 04, 2026 · 1,307,256 shares owned afterSep 04, 2026 · 1,308,498 shares owned afterSep 04, 2026 · 1,310,818 shares owned afterSep 04, 2026 · 1,314,210 shares owned afterSep 04, 2026 · 1,317,390 shares owned afterSep 04, 2026 · 1,321,352 shares owned afterSep 04, 2026 · 1,324,619 shares owned afterSep 04, 2026Sep 04, 2026
1,324,619Sep 04, 2026

These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.

Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells red
1 active days
Aug 05Sep 05
LessMore
Top insiders
By absolute net value across the selected period
2 insiders
  • KS
    Krishnan Krish SPRES · rank 1 · 0 buys · 13 sells
    -$9.0Mlast 09/04/undefined
  • KS
    Krishnan SumaPRES, R, D · rank 2 · 0 buys · 13 sells
    -$9.0Mlast 09/04/undefined
Recent filing activity
Most recent 12 transactions · color = transaction code

Filing detail checks

Secondary metrics for the selected period
Largest buy-
Largest sale$142M
10b5-1 detected26
Amended rows0

Filing-only signals

Deterministic matches in the selected period

No filing-only signal badges matched this period.

KRYS transaction history

Filters apply within this company and selected period by default
Reset
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
KRYSKrishnan Suma
PRESRD
sale10b5-1399-$14.6MS0.0%09/0409/04
KRYSKrishnan Suma
PRESRD
sale10b5-1826-$30.1MS0.0%09/0409/04
KRYSKrishnan Suma
PRESRD
sale10b5-11.32k-$48.4MS0.0%09/0409/04
KRYSKrishnan Suma
PRESRD
sale10b5-1565-$20.5MS0.0%09/0409/04
KRYSKrishnan Suma
PRESRD
sale10b5-11.99k-$72.2MS0.0%09/0409/04
KRYSKrishnan Suma
PRESRD
sale10b5-11.24k-$44.9MS0.0%09/0409/04
KRYSKrishnan Suma
PRESRD
sale10b5-12.31k-$83.6MS0.0%09/0409/04
KRYSKrishnan Suma
PRESRD
sale10b5-13.39k-$121MS0.0%09/0409/04
KRYSKrishnan Suma
PRESRD
sale10b5-13.18k-$113MS0.0%09/0409/04
KRYSKrishnan Suma
PRESRD
sale10b5-13.96k-$141MS0.0%09/0409/04
KRYSKrishnan Suma
PRESRD
sale10b5-13.26k-$116MS0.0%09/0409/04
KRYSKrishnan Suma
PRESRD
sale10b5-12.00k-$71.3MS0.0%09/0409/04
KRYSKrishnan Suma
PRESRD
sale10b5-1520-$18.4MS0.0%09/0409/04
KRYSKrishnan Krish S
PRES
sale10b5-1405-$14.8MS0.0%09/0409/04
KRYSKrishnan Krish S
PRES
sale10b5-1847-$30.9MS0.0%09/0409/04
KRYSKrishnan Krish S
PRES
sale10b5-11.35k-$49.4MS0.0%09/0409/04
KRYSKrishnan Krish S
PRES
sale10b5-1573-$20.8MS0.0%09/0409/04
KRYSKrishnan Krish S
PRES
sale10b5-12.00k-$72.8MS0.0%09/0409/04
KRYSKrishnan Krish S
PRES
sale10b5-11.21k-$43.8MS0.0%09/0409/04
KRYSKrishnan Krish S
PRES
sale10b5-12.26k-$81.6MS0.0%09/0409/04
KRYSKrishnan Krish S
PRES
sale10b5-13.35k-$120MS0.0%09/0409/04
KRYSKrishnan Krish S
PRES
sale10b5-13.14k-$112MS0.0%09/0409/04
KRYSKrishnan Krish S
PRES
sale10b5-13.98k-$142MS0.0%09/0409/04
KRYSKrishnan Krish S
PRES
sale10b5-13.29k-$117MS0.0%09/0409/04
KRYSKrishnan Krish S
PRES
sale10b5-12.02k-$72.1MS0.0%09/0409/04
KRYSKrishnan Krish S
PRES
sale10b5-1520-$18.4MS0.0%09/0409/04

Krystal Biotech, Inc. Insider Activity FAQ

SEC Form 4 context

Who recently reported transactions at Krystal Biotech, Inc.?

Krishnan Suma, Krishnan Krish S.

When was the latest reported open-market purchase?

No code-P purchase is available for this period.

When was the latest reported open-market sale?

Krishnan Suma reported a sale on Sep 04, 2026 valued at $14.6M. Read the SEC filing.

What is the recent purchase and sale balance?

Net open-market selling in the selected period was $17,966,069.36. Sales can occur for many non-investment reasons.

Where can I see the original SEC filing?

Every transaction row and latest-activity fact links to its original SEC filing.

What do these Form 4 transaction codes mean?

P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.